CMPX
Compass Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.02 / 10
Outperform
Fund-flow and analyst sentiment paint a more optimistic picture. A fund-flow score of 7.21/10 indicates robust capital inflows despite negative trends in block and medium-size flows. Analyst coverage is overwhelmingly bullish (Strong Buy 50%, Buy 50%) with a historical weighted rating of 4.82, implying confidence in future upside. Together, these elements suggest that negative short-term flows may be temporary, and institutional conviction could provide support.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-06
InstitutionD. Boral Capital
Times predicted8
Historical Win Rate62.5%
What is the market sentiment for CMPX?
- CMPX holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.02/10 (Outperform).
